IO

Xilio Therapeutics Announces Initiation of Enrollment for Phase 1 Combination Trial of XTX101, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, and Updated Phase 1 Monotherapy Data

Retrieved on: 
Thursday, December 7, 2023
IO, Patient, DCR, Lung cancer, Immunotherapy, ESMO, CRC, Diarrhea, Colorectal cancer, MSS, FC, Melanoma, Congress, Therapy, Cancer, Dermatitis, Liver disease, Oncology, Safety, Triple-negative breast cancer, NSCLC, Pharmaceutical industry

WALTHAM, Mass., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced the initiation of enrollment for its Phase 1 clinical trial of XTX101, an investigational tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab and reported updated monotherapy data from its ongoing Phase 1 clinical trial evaluating XTX101 in late-line patients with advanced and immuno-oncology (IO) refractory solid tumors. The data were presented at the European Society for Medical Oncology (ESMO) Immuno-Oncology Congress on December 7, 2023.

Key Points: 
  • The data were presented at the European Society for Medical Oncology (ESMO) Immuno-Oncology Congress on December 7, 2023.
  • XTX101 monotherapy was generally well-tolerated with treatment-related adverse events (TRAE) primarily Grade 1 or 2, and no patients discontinued treatment due to a TRAE.
  • In addition, as previously reported, no Grade 4 or 5 TRAEs were reported by investigators across all dosing levels and dosing intervals.
  • Xilio recently completed enrolling patients at the RP2D of 150 mg Q6W in monotherapy dose expansion and initiated enrollment in Phase 1 combination dose escalation to evaluate the safety, tolerability and efficacy of XTX101 in combination with atezolizumab.

Cidara Therapeutics Presents New Promising Preclincal Data on Novel Dual-Acting Drug-Fc Conjugates at ESMO Immuno-Oncology Annual Congress

Retrieved on: 
Thursday, December 7, 2023
IO, ESMO, IND, PD-1, Colorectal cancer, SAN, Congress, Therapy, CDTX, CD73, Patient, DFC, Pharmaceutical industry

SAN DIEGO, Dec. 07, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced the presentation of new preclinical data on its novel, multi-specific CD73/PD-1 targeting drug-Fc conjugate (DFC) candidate at the ESMO Immuno-Oncology (IO) Annual Congress. Cidara also presented new preclinical data on CBO421, its first-in-class CD73-targeting DFC. The conference is taking place December 6-8, 2023, virtually and in-person in Geneva, Switzerland.

Key Points: 
  • Cidara also presented new preclinical data on CBO421, its first-in-class CD73-targeting DFC.
  • The conference is taking place December 6-8, 2023, virtually and in-person in Geneva, Switzerland.
  • “We are thrilled to be presenting promising preclinical data on our novel multi-specific DFC in colorectal cancer for the first time at ESMO-IO this year,” said Jeffrey Stein, Ph.D., president and chief executive officer at Cidara.
  • The company plans to file an investigational new drug (IND) application in mid-2024 for CBO421.

Zafin™ Recipient of Best-in-Class Partner Award by BIAN Group

Retrieved on: 
Wednesday, December 6, 2023
IO, Ecosystem, Risk, Software as a service, Wells Fargo, Banking Industry Architecture Network, Video game

VANCOUVER, British Columbia, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Zafin™, the leading provider of SaaS product and pricing platform solutions for banks, announces today it has won the 2023 Banking Industry Architecture Network (BIAN) Best-in-Class Partner Award.

Key Points: 
  • VANCOUVER, British Columbia, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Zafin™, the leading provider of SaaS product and pricing platform solutions for banks, announces today it has won the 2023 Banking Industry Architecture Network (BIAN) Best-in-Class Partner Award.
  • In 2023, Zafin collaborated with the team at Wells Fargo to accelerate and ease integration between the bank core and the Zafin SaaS platform.
  • Zafin’s embrace of BIAN as a standard for interoperability aligns with Wells Fargo’s interest in promoting BIAN as a standard.
  • “We value our collaboration with the BIAN group to accelerate change and drive innovation for banks.

Cidara Therapeutics to Present New Preclinical Data on Novel Dual-Acting Drug-Fc Conjugates at ESMO Immuno-Oncology Annual Congress

Retrieved on: 
Thursday, November 30, 2023
IO, CDTX, Patient, ESMO, Congress, DFC, CD73, SAN, Therapy

SAN DIEGO, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced the company will present new preclinical data on its novel, dual-acting CD73/PD-1 targeting drug-Fc conjugate (DFC) candidate at the ESMO Immuno-Oncology (IO) Annual Congress.

Key Points: 
  • SAN DIEGO, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced the company will present new preclinical data on its novel, dual-acting CD73/PD-1 targeting drug-Fc conjugate (DFC) candidate at the ESMO Immuno-Oncology (IO) Annual Congress.
  • Cidara will also present new preclinical data on CBO421, its first-in-class CD73 targeting DFC.
  • The conference is taking place December 6-8, 2023, virtually and in-person in Geneva, Switzerland.
  • Presentation details are summarized below:

TheViewPoint Integrates with FreeWheel, Helping Streaming Publishers Process Direct IOs With the Speed and Automation of Programmatic

Retrieved on: 
Tuesday, November 28, 2023
IO, IOS, Ecosystem, Partnership, Hope, TVP, SAN, Freewheel, Infra, Advertising, Television, Automation

The two companies have partnered to introduce a new way for streaming platforms to modernize their ad sales through automation while also building a clearer demand path.

Key Points: 
  • The two companies have partnered to introduce a new way for streaming platforms to modernize their ad sales through automation while also building a clearer demand path.
  • Integrating with TVP Direct enables publishers working with FreeWheel to gain greater operational efficiency (which supports automation and scale), robust data security, and real-time reporting for optimization.
  • “This integration gives sellers using TVP Direct more automation and the most pure form of supply path optimization.
  • Tatari has long-standing relationships with all major streaming publishers, many who currently work with FreeWheel.

KBRA Assigns Preliminary Ratings to J.P. Morgan Mortgage Trust 2023-HE3 (JPMMT 2023-HE3)

Retrieved on: 
Wednesday, December 20, 2023
Banking, Professional Services, Finance, IO, United Wholesale Mortgage, FOCUS, RMBS, KBRA, Telescopic sight

KBRA assigns preliminary ratings to 7 classes of Mortgage Participation Pass-Through Certificates from J.P. Morgan Mortgage Trust 2023-HE3 (JPMMT 2023-HE3), a $257.8 million RMBS transaction sponsored by J.P. Morgan Mortgage Acquisition Corp. and FOCUS III Advisory, LLC.

Key Points: 
  • KBRA assigns preliminary ratings to 7 classes of Mortgage Participation Pass-Through Certificates from J.P. Morgan Mortgage Trust 2023-HE3 (JPMMT 2023-HE3), a $257.8 million RMBS transaction sponsored by J.P. Morgan Mortgage Acquisition Corp. and FOCUS III Advisory, LLC.
  • The transaction consists entirely of second lien home equity lines of credit (HELOCs).
  • The underlying pool is seasoned approximately two months and comprises 3,002 loans, with United Wholesale Mortgage, LLC (63.1%) and loanDepot.com, LLC (27.5%) representing the largest contributing originators.
  • Most of the loans feature 20-year repayment periods after initial draw windows of three or ten years.

Patti Engineering's Platinum Partnership with Arduino Enables Cost-Effective Digitalization and Streamlining of Projects

Retrieved on: 
Wednesday, December 20, 2023
Cloud, IO, Partnership, Software, Robotics, Engineering, Internet of things, Edge, Fourth Industrial Revolution, Video game

AUBURN HILLS, Mich., Dec. 20, 2023 /PRNewswire-PRWeb/ -- Patti Engineering, Inc., a leading control system integration company with offices in Michigan, Texas, and Indiana, today announced their partnership with Arduino, an open-source hardware pioneer with 32 million active developers worldwide. Patti Engineering joins the Arduino System Integrators Partnership Program as a Platinum Partner, designed to fuel growth for professional service companies integrating Arduino technology in commercial projects for enterprise clients.

Key Points: 
  • Patti Engineering joins the Arduino System Integrators Partnership Program as a Platinum Partner, designed to fuel growth for professional service companies integrating Arduino technology in commercial projects for enterprise clients.
  • The partnership with Arduino enables Patti Engineering's engineers to work with clients further on digitalizing plant-floor data by connecting machinery to the Edge and Cloud .
  • Patti Engineering has developed extensive industry expertise throughout the rigorous Arduino partner application process which resulted in Platinum status.
  • As a Platinum Partner focusing on hardware, software, cloud, and general solutions, Patti Engineering receives access to select supply agreements from Arduino.

Voices™ Marketplace seeking digital publisher partnerships

Retrieved on: 
Monday, December 18, 2023
IO, Interactive media, SVP, Wavefront, Privacy, BIPOC, Marketplace, Voices, Multimedia

NEW YORK, Dec. 18, 2023 /PRNewswire/ -- In response to tremendous advertiser demand for scale in reaching diverse populations with authenticity, Infinity Partnerships is presently seeking new digital publishing partners to participate in the Voices™ Marketplace.

Key Points: 
  • NEW YORK, Dec. 18, 2023 /PRNewswire/ -- In response to tremendous advertiser demand for scale in reaching diverse populations with authenticity, Infinity Partnerships is presently seeking new digital publishing partners to participate in the Voices™ Marketplace.
  • The Voices™ Marketplace , powered by AdGrid launched in September to solve the problem of scale in multicultural digital advertising.
  • The innovative platform has been wildly successful, and Infinity Partnerships is actively seeking multicultural and general market publishers to join the marketplace.
  • The Voices Marketplace™ is a joint venture between Infinity Partnerships , the most inclusive advertising technology consultancy and AdGrid.

IO Biotech Appoints Helen Collins, MD, to its Board of Directors

Retrieved on: 
Monday, November 13, 2023
Bryn Mawr College, Neck, Acquisition, Therapy, BTK, Head, Gilead Sciences, Cancer, Patient, Research, Lung cancer, Carcinoma, PD-1, National Parks Development Committee, Johns Hopkins Hospital, Doctor of Philosophy, IO, BET, Drug development, Amgen, Pharmaceutical industry, MD

NEW YORK, Nov. 13, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune modulating cancer vaccines based on its T-win® technology platform, announced the appointment of Helen Collins, MD, to its board of directors.

Key Points: 
  • NEW YORK, Nov. 13, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune modulating cancer vaccines based on its T-win® technology platform, announced the appointment of Helen Collins, MD, to its board of directors.
  • Dr. Collins is an industry veteran with significant experience in oncology/hematology drug development and will serve on the Research and Development Committee of the Board.
  • “We are pleased to welcome Helen, an accomplished healthcare executive with extensive drug development and corporate strategy experience, to our Board of Directors,” said Mai-Britt Zocca, PhD, President and CEO of IO Biotech.
  • Dr. Collins currently serves on the board of directors for Kura Oncology.

Zafin™ Recipient of Best-in-Class Partner Award by BIAN Group

Retrieved on: 
Wednesday, December 6, 2023
Technology, Finance, Fintech, Banking, Professional Services, Digital Cash Management, Digital Assets, Software, Networks, Data Management, IO, Wells Fargo, Banking Industry Architecture Network, Software as a service, Video game, Zafin, BIAN, Orchestration

Zafin™, the leading provider of SaaS product and pricing platform solutions for banks, announces today it has won the 2023 Banking Industry Architecture Network (BIAN) Best-in-Class Partner Award.

Key Points: 
  • Zafin™, the leading provider of SaaS product and pricing platform solutions for banks, announces today it has won the 2023 Banking Industry Architecture Network (BIAN) Best-in-Class Partner Award.
  • The company was honored with this distinction for the development of Zafin Integrate and Orchestrate (IO) a foundational technology platform and BIAN based solution.
  • Zafin’s embrace of BIAN as a standard for interoperability aligns with Wells Fargo’s interest in promoting BIAN as a standard.
  • “We value our collaboration with the BIAN group to accelerate change and drive innovation for banks.”